Event Date: Thursday, March 19, 2026        
Event Time: 1:00 - 2:00 pm ET        

Please Note: All times are Eastern. This webinar will begin at 1:00 pm Eastern / 12:00 pm Central / 11:00 am Mountain / 10:00 am Pacific.

Description

MASH is a progressive liver disease within the MASLD spectrum, and fibrosis is the strongest predictor of liver related outcomes. In endocrinology, many high-risk patients have silent disease and can progress quickly once significant fibrosis develops. This webinar gives a practical approach to identifying who to assess, how to use noninvasive tests to stratify fibrosis risk, and how to understand the key components of effective management.

Learning Objectives

After attending this webinar, participants will be able to:
1. Define MASH as a progressive disease.
2. Recognize the severe consequences of MASH.
3. Understand the role of hepatic thyroid hormone in MASH and the importance of early patient identification.
4. The importance of effective and timely MASH management.

Agenda

1. MASH definition and progression
2. Why fibrosis drives risk
3. Who to assess in endocrine practice
4. Noninvasive testing approach
5. Referral and shared management
6. Q&A

Sponsor

This webinar is sponsored by Madrigal Pharmaceuticals.

Disclaimer

There is no CE/CME credit for this activity.

Pricing

This event is FREE for ADCES members and non-members.

Live webinar registration does not include access to the recorded webinar. The recorded webinar will be available for separate registration within 2 weeks of the live event at adces.org/store/online-education.

Speaker

Taher Moderressi, MD, FNLA 
Advocare Princeton Cardiometabolic Health 
Pennington, NJ

Dr. Taher Modarressi is an endocrinologist at Advocare Princeton Cardiometabolic Health in Pennington, New Jersey. He is board certified in endocrinology, diabetes and metabolism, clinical lipidology, obesity medicine, and internal medicine. 

He earned his bachelor's degree from Princeton University and his medical degree from NYU School of Medicine, where he was inducted into Alpha Omega Alpha. He completed an internal medicine residency at Massachusetts General Hospital, Harvard Medical School, and then an endocrinology, diabetes and metabolism fellowship at the University of Pennsylvania. 

Dr. Modarressi serves on several scientific advisory boards and is active in clinical research and publication. His work focuses on cardiovascular risk reduction across diabetes, obesity, lipid disorders, and emerging MASLD and MASH therapies, including identification and management of MASLD and MASH in cardiometabolic populations and real world uptake of these therapies. He also reviews for multiple journals, including The Journal of Clinical Endocrinology and Metabolism and the Journal of Clinical Lipidology.

Test Your Computer

To ensure that your participation is successful, please test your system as soon as possible so if you do have technical challenges, you will have time to get them sorted out. Click here to test your computer.

System Requirements

You must have a broadband wired or wireless (3G or 4G/LTE) internet connection to attend this event. Click here for operating system requirements.